|
**Overview**: Beta-2-Glycoprotein 1 Panel**Introduction**: The Beta-2-Glycoprotein 1 Panel is a diagnostic tool designed to screen for thrombophilia using serum samples. In India, antiphospholipid syndrome (APS) and thrombophilia are underrecognized causes of recurrent thrombosis, miscarriage, and obstetric complications (prevalence ~1-5 percent in women with recurrent pregnancy loss). Beta-2-glycoprotein 1 antibodies (IgG, IgM, IgA) are key markers for APS diagnosis. High morbidity from underdiagnosis in women with infertility/miscarriage, limited rheumatology/obstetrics access in rural areas, delayed anticoagulation leading to stroke or fetal loss. Per immunology practices aligned with ICMR and Indian Society of Obstetrics guidelines, the test employs immunoassay for IgG/IgM/IgA detection over 1-2 days with high specificity, valuable for confirming thrombophilia risk. This diagnostic falls under autoimmune screening and targets patients with suspected APS or recurrent thrombosis, addressing accurate detection to guide anticoagulation. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Beta 2 GP1 Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Beta-2-GP1 identified in 1990s; in India, prominence with APS registries.**Purpose**: The test screens for 3 parameters including Beta 2 Glycoprotein IgG to guide thrombophilia assessment, confirm APS risk, inform anticoagulation.**Test Parameters**: 1. Beta 2 Glycoprotein IgG, 2. Beta 2 Glycoprotein IgM, 3. Beta 2 Glycoprotein IgA.**Pretest Condition**: No fasting required; patients should report thrombosis, recurrent miscarriage, or APS symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on thrombosis, pregnancy loss, family thrombophilia history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated thrombophilia including stroke/miscarriage, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive antibodies indicate thrombophilia/APS risk, necessitating specialist input. Negative may require follow-up if symptoms persist.**Specialist Consultation**: Hematologists or rheumatologists should be consulted for management.**Additional Supporting Tests**: Lupus anticoagulant, anti-cardiolipin for confirmation.**Test Limitations**: May require repeat testing; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, Thrombophilia Studies India 2023. |
